Study guide

11.2 Bone and Musculoskeletal Imaging

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

11.2 Bone and Musculoskeletal Imaging

Key Takeaways Explain This Topic AI

Bone scintigraphy uses Tc-99m MDP/HDP (~20–30 mCi adult) with delayed imaging at about 2–4 hours; hydrate and void to clear soft tissue and bladder

Three-phase (flow, blood pool, delayed) and four-phase (add 24-hour) studies help separate cellulitis from osteomyelitis and characterize complex MSK infection/trauma

SPECT and SPECT/CT refine spine and complex anatomy; NaF-18 PET/CT is a high-sensitivity bone-seeking PET alternative when available

Indications include metastases, occult fracture, infection, RSD/CRPS patterns, and prosthesis workups—always document surgery, trauma, and hardware

Normal variants (growth plates, asymmetric uptake, urine contamination) are high-yield traps for false-positive “lesions”

Last updated: August 2026

11.2 Bone and Musculoskeletal Imaging

Quick Answer: Tc-99m MDP/HDP maps osteoblastic activity (~ 20–30 mCi , image 2–4 h ). Use limited , whole-body , 3-phase , or 4-phase protocols; add SPECT/SPECT-CT . NaF PET is the PET bone alternative. Know indications , prep , phase roles , and normal variants .

Agents and Physiology (Procedure Focus)

Tc-99m medronate (MDP) and oxidronate (HDP) bind bone mineral by chemiadsorption to hydroxyapatite where osteoblastic activity and blood flow are high. Procedure questions assume you already know the chemistry (Domain III) and now execute the right protocol for the clinical question.

  • Agent Role in MSK imaging
  • Tc-99m MDP/HDP Standard planar/SPECT bone scan
  • F-18 sodium fluoride (NaF) PET/CT bone imaging—high bone-to-background, rapid kinetics
  • Protocol Menu
  • Limited Bone Scan

Spot views of a region (e.g., hands, feet, lumbar spine) when disease is localized. Still inject standard activity unless pediatric/weight-based rules apply; image the area of interest plus comparison views as ordered.

Whole-Body Bone Scan

Anterior and posterior head-to-toe passes (plus spots as needed) for metastatic surveys and multifocal disease. Typical adult dose ~20–30 mCi (740–1110 MBq) IV ; delayed imaging ~2–4 hours . Hydrate; void immediately before scanning; remove metal; note pacemakers/ports.

Three-Phase Bone Scan

Ordered for infection , trauma , and complex regional pain patterns when blood flow and soft-tissue phases matter.

  • Phase Timing What it shows (tech-level)
  • Flow (dynamic) Immediate dynamic frames over ROI during/after bolus Regional perfusion
  • Blood pool (soft tissue) ~5–10 min (immediate static) Hyperemia / soft-tissue inflammation
  • Delayed (bone) ~2–4 h Osteoblastic bone reaction

Interpretation roles for the technologist: obtain a true bolus over the correct region; keep the patient still; label left/right; do not “skip flow” if ordered for osteomyelitis vs cellulitis. Physician reads patterns (e.g., all three phases hot in osteomyelitis vs soft-tissue-only in cellulitis)—your job is complete, timed, quality phases.

Four-Phase Bone Scan

Adds a ~24-hour delayed set. Used when soft-tissue clearance is poor (renal failure, edema) or when separating persistent soft-tissue activity from true bone uptake in difficult infection cases. Schedule the return visit and reinforce hydration/voiding.

SPECT and SPECT/CT

SPECT improves contrast for spine, skull base, and joints. SPECT/CT adds anatomic correlation for hardware, facets, and small bones—critical for specificity after trauma or surgery. Position to include the clinical site; minimize motion; document pain-limited positioning.

NaF-18 PET/CT

NaF is taken up in bone proportional to blood flow and osteoblastic activity. Typical adult activity is often ~5–10 mCi class (protocol-specific); uptake is rapid with imaging commonly ~30–60+ minutes after injection. PET/CT provides tomographic whole-skeleton surveys with high sensitivity for osteoblastic mets. Prep still includes hydration and voiding; follow PET timing and CT parameters per SOP.

Indications Map

  • Clinical question Typical approach
  • Osseous metastases (prostate, breast, lung, etc.) Whole-body MDP/HDP ± SPECT; or NaF PET
  • Osteomyelitis vs cellulitis Three-phase ( ± 4-phase, WBC/other as ordered)
  • Occult / stress fracture Limited or whole-body delayed ± SPECT
  • RSD / CRPS Three-phase periarticular pattern evaluation
  • Prosthesis pain Three-phase ± complementary infection imaging
  • Paget, metabolic surveys Whole-body delayed
  • Patient Preparation

Explain procedure length and need to hold still; screen pregnancy.

Encourage oral hydration after injection unless fluid-restricted.

Void before delayed imaging; catheterize if ordered for pelvic clarity.

Remove jewelry and metal; document recent surgery, fractures, dental work, and injections (extravasation can cause soft-tissue hot spots).

For flow phase: place camera over ROI before injection; secure IV; inject as a bolus.

Normal Variants and Interpretation Traps

  • Finding Trap / teaching point
  • Pediatric growth plates Symmetric intense metaphyseal uptake—normal, not “mets”
  • Asymmetric uptake Degenerative joint disease, weight-bearing stress, or prior trauma—correlate clinically
  • Skull suture / sinus activity Can mimic lesions on planar views—SPECT/CT helps
  • Bladder / urine contamination Pelvic false lesions—wash skin, change garments, post-void images
  • Injection site / extravasation Soft-tissue focus away from skeleton
  • Renal failure High soft-tissue background; consider delayed 24-h views
  • Flare phenomenon Temporary increase in met intensity after therapy—clinical context
  • Cold lesions Purely lytic non-reactive disease may be photopenic

Extraosseous uptake (kidneys, stomach free Tc, liver-spleen colloid contamination) is a QC/pathology differential covered with agents—but on procedure day you still recognize and document it and notify the interpreting physician.

Three-Phase: Tech Quality Checklist

Correct FOV for symptomatic region (include comparison side when useful).

True dynamic flow—not a delayed “blood pool only” when flow was ordered.

Identical positioning for blood-pool and delayed spots when possible.

Whole-body or additional spots if multifocal disease is possible.

SPECT/CT when ordered for spine/complex hardware.

Protocol Snapshot Table

  • Protocol When used Key timing
  • Limited spots Focal symptoms Delayed 2–4 h
  • Whole-body Staging / multifocal Delayed 2–4 h
  • 3-phase Infection / trauma / CRPS Flow + pool + 2–4 h
  • 4-phase Problem clearance / complex infection Add ~24 h
  • SPECT/CT Localization After delayed planar or dedicated
  • NaF PET/CT High-end bone survey ~30–60+ min post-injection

Bone procedure mastery is right phases + clean delayed images + variant awareness —that is what CNMT clinical items reward.